Sunbelt Securities Inc. Has $1.50 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Sunbelt Securities Inc. lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 17.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,586 shares of the company’s stock after purchasing an additional 1,834 shares during the period. Sunbelt Securities Inc.’s holdings in Novo Nordisk A/S were worth $1,499,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. 1620 Investment Advisors Inc. acquired a new position in Novo Nordisk A/S during the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at $25,000. Gilliland Jeter Wealth Management LLC raised its holdings in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares during the period. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S during the 3rd quarter worth $28,000. Finally, Abound Wealth Management boosted its holdings in Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after acquiring an additional 157 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $111.69 on Thursday. The firm has a market capitalization of $501.21 billion, a PE ratio of 36.15, a PEG ratio of 1.41 and a beta of 0.40. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1-year low of $94.96 and a 1-year high of $148.15. The business’s 50 day moving average is $110.98 and its 200-day moving average is $126.71.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NVO shares. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets cut their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $150.40.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.